On September 2, 2016 LeadArtis reported its participation as coordinator of the IBIMAB project (Cancer immunotherapy with bispecific costimulatory antibodies) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS 2016 Collaboration program (Press release, LeadArtis, SEP 2, 2016, View Source [SID:SID1234515139]). IBIMAB counts with collaborators such as the internationally regarded research institutions: Centro de Investigación Médica Aplicada-CIMA (Pamplona, Spain), Hospital Universitario Puerta de Hierro-HUPH (Madrid, Spain) and Instituto de investigaciones biomédicas Alberto Sols-IIBm-CSIC (Madrid, Spain). The MINECO’s funding demonstrates the support of LeadArtis technology and main objectives.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Some of the most effective cancer immunotherapy strategies are based on the modulation of molecular interactions dubbed immune check-points using monoclonal antibodies (mAbs). LeadArtis generates bispecific hexavalent trimerbodies (BHTs) exploiting the expression of two cell surface antigens, one a costimulatory molecule on the T cells and the other a tumor-associated antigen (TAA) on the tumor cells. The anti-TAA specificity allows efficient location of the BHT into the tumor deposits, providing a more efficient interaction with the costimulatory antigen expressed on the surface of tumor infiltrating T lymphocytes. Our company focuses on two clinically validated mechanisms of action synergistic when combining individual mAbs (IgG type). LeadArtis will use its proprietary trimerbody technology to generate a fully human bispecific hexavalent antibody as candidate for development.
LeadArtis is the leading company aiming to bring to the market cancer immunotherapeutic trimerbodies. Despite recent advances in the field, most of the current initiatives are early stage and exploratory. Currently, most of current immune-checkpoint blockers in development are conventional monoclonal antibodies (mAbs); comparatively, recombinant antibody technologies are strongly positioned and shortly will become preferred for clinically validated mechanisms of action. The trimerbody added value is multivalence and multispecificity, small size & ease of manufacturing to generate more effective compounds.